Nikang Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nikang Therapeutics's estimated annual revenue is currently $7.8M per year.(i)
  • Nikang Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Nikang Therapeutics has 50 Employees.(i)
  • Nikang Therapeutics grew their employee count by 28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$79.1M5100%N/AN/A
#2
$0.9M620%N/AN/A
#3
$1.9M129%N/AN/A
#4
$5.4M3521%N/AN/A
#5
$0.8M5-29%N/AN/A
#6
$8.7M5624%N/AN/A
#7
$1.4M9-31%N/AN/A
#8
$1.1M70%N/AN/A
#9
$36M23219%N/AN/A
#10
$15.5M100-2%N/AN/A
Add Company

NiKang Therapeutics, Inc. is a privately-held biotech company focused on developing novel small molecule oncology drug discovery. Their mission is to discover and develop first-in-class, and/or best-in-class small molecule targeted therapies and immuno-oncology (I-O) drugs to help cure cancers.

keywords:N/A

N/A

Total Funding

50

Number of Employees

$7.8M

Revenue (est)

28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nikang Therapeutics's People

NameTitleEmail/Phone
1
Associate General CounselReveal Email/Phone
2
Executive Director, ControllerReveal Email/Phone
3
VP Clinical DevelopmentReveal Email/Phone
4
VP, Regulatory Affairs and Quality AssuranceReveal Email/Phone
5
VP Intellectual PropertyReveal Email/Phone
6
VP ChemistryReveal Email/Phone
7
Senior Director, BiostatisticsReveal Email/Phone
8
Senior Director CMCReveal Email/Phone
9
Associate DirectorReveal Email/Phone
10
Sr. Director, Drug Product Development and ManufacturingReveal Email/Phone

Nikang Therapeutics News

2022-03-30 - NiKang Therapeutics Presents Preclinical Data Highlighting ...

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.4M50-4%N/A
#2
$12.6M5011%N/A
#3
$7.2M5028%N/A
#4
$5.8M50-11%N/A
#5
$8M5085%N/A